EGFR mutations are caused by errors in the DNA of the epidermal growth factor receptor gene, a gene that controls how cells grow and divide. Most EGFR mutations linked to cancer are somatic, meaning they develop during a person’s lifetime rather than being inherited. They arise from a combination of environmental exposures, hormonal influences, and genetic susceptibility, though in many cases no single clear trigger can be identified.
Somatic vs. Inherited Mutations
The vast majority of EGFR mutations in lung cancer are somatic. These are not passed down from parents. Instead, they occur when something goes wrong during cell division in lung tissue, producing a copying error in the EGFR gene. The result is a protein that is permanently switched “on,” telling cells to keep growing and dividing when they should stop. The two most common forms are a small deletion in a region called exon 19 and a single-letter swap known as L858R in exon 21. Together, these account for the majority of EGFR mutations found in lung adenocarcinoma.
A small number of EGFR mutations are germline, meaning they are inherited and present in every cell from birth. The best-studied example is the germline T790M mutation, which appears in fewer than 1% of all lung cancers and roughly 2% of EGFR-mutant lung cancers. In mouse models, this mutation alone can induce tumor formation. In people, it appears to act as a weak initial trigger. Carriers typically develop cancer only after acquiring a second somatic mutation or being exposed to environmental stressors like smoking or air pollution. This follows what geneticists call the “two-hit” model: one inherited vulnerability plus one acquired error equals uncontrolled growth.
Why Family History Matters
A family history of cancer significantly raises the likelihood of an EGFR mutation being present in a lung tumor. In a study of Taiwanese never-smokers with lung cancer, patients who had any family history of cancer were nearly six times more likely to carry an EGFR mutation than those without family history. For patients with a family history specifically of lung cancer, that figure jumped to 7.5 times more likely. Even a family history of cancers in other organs raised the odds fivefold.
This does not necessarily mean a specific EGFR mutation was inherited in every case. It may reflect a shared genetic background that makes cells more vulnerable to the kind of DNA errors that produce EGFR mutations. Some inherited variants appear to make the EGFR gene itself unstable, predisposing cells to additional mutations over time.
The Role of Air Pollution
Fine particulate matter (PM2.5) from vehicle exhaust, industrial emissions, and wildfire smoke is one of the most studied environmental links to EGFR-mutant lung cancer. Importantly, PM2.5 does not appear to cause EGFR mutations directly the way cigarette smoke causes other DNA damage. Instead, it promotes cancer in cells that already carry a pre-existing EGFR mutation.
The mechanism works like this: PM2.5 particles lodged in the lungs trigger an inflammatory response. Immune cells called macrophages flood into lung tissue and release an inflammatory signal called interleukin-1β. That signal acts on a specific type of deep lung cell (alveolar type II cells) that already harbors a dormant EGFR mutation, pushing those cells into a stem-cell-like growth state. In other words, air pollution does not write the mutation into DNA. It wakes up mutations that are already there and would otherwise remain harmless.
This finding helps explain why EGFR-mutant lung cancer can develop in people who have never smoked and have no obvious carcinogen exposure. Many people may carry low-level EGFR mutations in their lung tissue that never progress to cancer unless an inflammatory trigger tips the balance.
Why EGFR Mutations Are More Common in Certain Groups
EGFR mutations are not evenly distributed across populations. They appear in roughly 57% of Asian patients with lung adenocarcinoma, compared to about 20% of white patients and 22% of Black patients. The reasons for this disparity are not fully understood, but they likely involve inherited genetic differences in how the EGFR gene is regulated and repaired across populations.
Sex also plays a major role. Women develop EGFR-mutant lung cancer at higher rates than men, and hormonal signaling appears to be a key reason. Estrogen can directly activate the EGFR pathway through several mechanisms. It triggers a receptor-mediated process that mimics the effects of the growth signals EGFR normally responds to. It also stimulates downstream growth pathways (the same ones that EGFR activates) independently, essentially doubling the growth signal. In lung cancer cells, high levels of an enzyme that produces estrogen are significantly correlated with the presence of EGFR mutations, creating a feedback loop of estrogen production and EGFR-driven growth.
Research on patients with both breast cancer and lung cancer found a striking pattern: among those whose lung tumors carried EGFR mutations, over a third also had hormone receptors (estrogen or progesterone receptors) present in their lung tissue. Among patients without EGFR mutations, zero had hormone receptors in their lung tumors. Every single patient with hormone-receptor-positive lung tissue also tested positive for an EGFR mutation.
What Radon and Secondhand Smoke Don’t Explain
Radon gas and secondhand smoke are well-established causes of lung cancer overall, but research has not found a consistent link between either exposure and EGFR mutations specifically. A study of former-smoking and never-smoking U.S. women found no dose-response relationship between residential radon levels and EGFR mutations. In fact, mutation frequency appeared slightly higher at low radon doses and decreased at higher doses, a pattern the researchers attributed to chance rather than a biological effect. Passive smoking showed a similar lack of consistent association. This suggests that EGFR mutations arise through pathways distinct from the DNA damage caused by radiation or tobacco carcinogens.
Secondary Mutations During Treatment
A second category of EGFR mutations develops not as the original cause of cancer, but as a response to treatment. When EGFR-mutant lung cancer is treated with targeted drugs that block the EGFR protein, the cancer can evolve resistance by acquiring additional mutations in the same gene.
The most common resistance mutation is T790M, which appears in 50 to 60% of patients whose cancer stops responding to first-generation targeted therapies. This mutation changes the shape of the drug’s binding site on the protein, making it much harder for the drug to attach. Specifically, it increases how tightly the mutant protein grips its natural fuel (ATP), outcompeting the drug. Newer drugs were designed to overcome T790M, but the cancer can adapt again. A mutation called C797S emerges in 10 to 20% of patients treated with the third-generation drug osimertinib. This mutation removes the exact chemical anchor point the drug uses to lock onto the protein.
These resistance mutations are driven by evolutionary pressure. Among billions of cancer cells, a tiny fraction may randomly acquire a second mutation that makes them immune to the drug. As the drug kills off sensitive cells, the resistant ones survive and multiply until they dominate the tumor. The mutations themselves are random copying errors, but the selection pressure from treatment determines which errors persist.
Putting the Causes Together
EGFR mutations in lung cancer rarely have a single cause. The emerging picture is one of layered risk: a genetic background (ethnic, familial, or hormonal) that makes the EGFR gene more prone to errors, combined with environmental exposures that either introduce those errors or promote the growth of cells that already carry them. For many patients, particularly never-smoking women of East Asian descent, the convergence of inherited susceptibility, estrogen-driven signaling, and inflammatory triggers from air pollution creates conditions where EGFR-mutant cancer can develop without any traditional risk factor like smoking. For others, a rare inherited mutation sits quietly for decades until a second hit, whether from the environment or from random chance during cell division, sets the process in motion.